Hims & Hers Expands Access To Wegovy And Ozempic Through Novo Nordisk Partnership; Offering Lower-Cost Treatment Options

Hims & Hers Health, Inc. (NYSE: HIMS) has partnered with Novo Nordisk to expand access to a range of FDA-approved GLP-1 medications, including Wegovy®, the only FDA-approved weight loss pill. This collaboration aims to provide eligible customers with more affordable treatment options, with prices starting at $149 a month. The available medications include various dosages of Wegovy® and Ozempic®, which, while not approved for weight loss, is used for Type 2 diabetes treatment. This move positions Hims & Hers as the largest global consumer health platform for affordable access to approved medications.